# **CV: DR.CHOW TING SOO**

Full name and title:	DR. CHOW TING SOO MMC: 33721 NSR:128999
Nationality:	Malaysian
Professional Address:	Hospital Pulau Pinang Medical Department Infectious Disease Unit Jalan Residensi 10990 Pulau Pinang Malaysia
Present Position: Since:	Consultant Physician, Infectious Disease Consultant, Head of Infectious Disease Unit Infectious Disease Unit Department of Internal Medicine Hospital Pulau Pinang Since July 2006 -OCT 2017  Penang State Infection Prevention and Control Coordinator and Hospital Pulau Pinang Infection Control Officer since Oct 2016.
	Sessional Consultant Physician and Infectious Disease Gleneagles Hospital Jalan Pangkor Penang
Main qualification:	M.D. UNIVERSITY SCIENCE of MALAYSIA M.R.C.P Royal College of Physicians. (Edin) Fellowship in Infectious Diseases 2006 FRCP (UK) 2021

# **Medical experience**

#### June 1996-June 1997

Hospital Pulau Pinang, Paediatric and Surgery Department, Obstetric House Officer.

#### **June 1997-October 1997**

Hospital Pulau Pinang, Medical Department, Medical Officer. October 1997-February 1998

Hospital Pulau Pinang, Surgical Department, Medical Officer

# February 1998-October 2000

Hospital Seberang Jaya, Medical Department, Medical Officer

# October 2000-August 2002

Hospital Seberang Jaya, Medical Department, Clinical Specialist

# August 2002-March 2003

Hospital Pulau Pinang, Infectious Disease Unit, Medical Department, Clinical Specialist

# March 2003-September 2004

Hospital Kuala Lumpur, Infectious Disease Unit, Medical Department, Clinical Specialist with subspecialty training in infectious disease.

# September 2004 – September 2005

Hospital Pulau Pinang, Infectious Disease Unit, Medical Department, Clinical Specialist

## **September 2005 – July 2006**

St. Vincent's Hospital Darlinghurst, Sydney, Australia, Infectious Disease Unit and clinical microbiology training.

#### **July 2006 till OCT 2017**

Hospital Pulau Pinang, Infectious Disease Unit, Medical Department, Consultant and Head of Unit.

## **OCT 2016**

## July 2006 till now

Consultant in Medical Department Infectious Disease Unit

Hospital Pulau Pinang

Appointed state IPC coordinator of state Penang, and Hospital Chief of infection prevention and control officer

Head of unit IPC HPP 2016

Appointed as Advisor for State ID services in Penang since 2020

2022

Appointed as Subspecialty Education Subcommittee in ID under MMC (MPM) Jan 2020 till Jan 2022

appointed as Chair person Pengerusi Subspecialty Sub committee for Education in ID , Medical Education Committee MMC 2022-2023

Appointed as AJK Task Force Committee for Covid 19 HPP 2020-2022

2023

appointed as Deputy Head of service for ID under MOH Timbalan Ketua Perkhidmatan Penyakit berjangkit KKM 2/1/2023-31/10/2024

ahli jawatankuasa kerja ubat ubatan KKM (feb 2023-dec2024)

ahli anti infektif

# Work Experience In Infectious Diseases

Hospital Kuala Lumpur is a tertiary referral hospital with more then 2000 bed occupancy. It has about 400 Medical beds and 28 intensive care beds. My work, for the past one and a half year in infectious disease unit training includes general medical work, as general physician, and work in the infectious diseases unit as well.

- HIV outpatient clinic on 4 days a week frequency, seeing about 30 patients per week.
- General infectious disease clinic other than HIV once a week, seeing malaria, leptospirosis, Melioidosis etc.
- Inpatient work consists of taking care of HIV patients with opportunistic infection and adverse effect of ARVT, in addition to other general infectious diseases like Melioidosis, infective endocarditis.
- Reviewing critically ill patients in intensive care unit, including general ICU, Nephrology ICU, burns ICU and Neurology ICU for complicated infectious diseases.
- Participating in the SARS management team during the epidemic in year 2003.
- Reviewing patients in National Heart Center with complicated infectious diseases.
- Management of occupational exposure of biohazard needle sticks injury.
- Antibiotic Audit for Kuala Lumpur Hospital.

Hospital Penang is a tertiary referral hospital for Northern Malaysia with 1000 beds occupancy. It has about 250 medical beds and 30 intensive beds. My work in infectious diseases unit includes the above and

- Member of infection control committee
- Training of infection control link personals.
- Member of antibiotic committee in Hospital Penang.
- Honorary lecturer for Penang Medical College and College of Nursing.
- Committee for technical committee for Pandemic Influenza

In St. Vincent's Hospital Sydney, I am reviewing cases with complicated infectious diseases in ICU, transplant related infectious diseases, HIV/AIDS and laboratory work in microbiology unit.

July 2006 till present,

Appointed as Consultant Physician in Medical Department and infectious Disease Physician in Infectious Disease Unit under Medical Department of Hospital Pulau Pinang.

Working committee of Clinical Practice Guidelines for HIV infected pregnant Lady 2007

Working committee of Clinical Practice Guidelines for Dengue Infection in Adult 2007

Working Committee for State and Hospital Pandemic Flu Preparedness Plan in Penang.

Member of Infection Control Committee HPP

Member of Antibiotic Guidelines Committee for Penang Hospital.

Member of Community Service AIDS Penang Member of Family Development And Health Association Penang

Committee Out Reach Program for the minority group Committee Outreach Program for Youth

The secretary of Malaysia Society of HIV Medicine (2011-2015) The Secretary of Clinical Research of Penang (2011- now)

Working Committee CPG Management of dengue in adult 2015

Chairman of infection control unit HPP 6/10/2016

Maedical advisory Board committee HPP 2017-2019 (Infection Control)

JKTU committee HPP (2017-2019)

Patient Safety Goal Committee HPP 2017

President MASHM 2018 -

# **Relevant Clinical Research Experience (list indication and phase of previous trials)**

- 2004 Co investigator for BMS trials with atazanavir.
- 2007 IV Tygercycline trial as primary investigator
- 2007 TMC 114 226 early access program for HIV patient as primary investigator
- 2007 TMC 114 229 trial for HIV patient as primary investigator
- 2007 Research on the need of HIV infected young adults as co-investigator
- 2008 Effectiveness of clinical practice guidelines in management of dengue in adult co investigator
- 2009 PROUD study primary investigator
- 2010 Exploratory Study on the Virological and Immunological Improvement in HIV-Infected Patients Receiving Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)- Containing HAART Versus Patients Receiving Protease Inhibitors (PIs)-Containing HAART
- 2010 Second Line Study (International Trial, Multicentre)
- 2011 ASSESSING THE PRESCRIBING PATTERN AND DOCTORS PERCEPTION ON SURGICAL ANTIMICROBIAL PROPHYLAXIS IN HOSPITAL PULAU PINANG
- 2011 Malaysia Candidemia Study (MACAS)
- 2012 Minimal inhibitory concentration for MDR Acinetobacter in sterile site and tracheal aspirate in Hospital Penang
- 2013 SERS for NS1 study
- 2013 HIV 1 genotyping and resistant prevalence study in Malaysia
- 2014- 2016 ONCEMRK study (A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily Versus Raltegravir (MK-0518) 400 mg Twice Daily, Each in Combination With TRUVADA(TM), in Treatment-Naive HIV-1 Infected Subjects)
- 2014- 2016 Hand study
- 2016 A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia
- 2016 HIV LOC (HIV Linkage of Crae Study Penang State
- 2016 A Prospective Study to Characterize the Management and Outcome of Clostridium Difficile Infection in Asian Pacific Countries
- 2017 A Study to Explore the Distribution of Influenza, RSV and hMPV in Adults Hospitalized With Acute Respiratory Tract Infectio
- 2018 Clinical and Microbiological Evaluation on Pseudomonas Aeruginosa Infection in Hospital Pulau Pinang

2018 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults

2019 A phase IIIB/IV randomised open-label trial to compare dolutegravir + pharmaco-enhanced darunavir versus recommended standard of care antiretroviral regimens in patients with HIV infection who have failed recommended first line therapy: the D2EFT study.

2019 A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM-NEGATIVE BACTERIA PRODUCING METALLO-B-LACTAMASE (MBL)

2019 Survey of Central Venous Catheter Care Bundle On Compliance and CLABSI Rate In Medical Wards, Hospital Pulau Pinang.

# 2019 Clinical and Microbiological Evaluation on Pseudomonas Aeruginosa Infection in Hospital Pulau Pinang

#### 2020

Carbapenem Resistant Enterobacteriaceae Acquisition Rate and Risk Factors in General Intensive Care Unit ,Hospital Pulau Pinang

2020

Lead investigator WHO Solidariry Trial

Nontyphoidal Salmonella Infected Aortic Aneurysm: Case report and brief reviewClinical Audit / Quality Assurance / Quality Control

# HOSPITAL PULAU PINANG

-Clinical Outcome of Staphylococcus Aureus Bacteremia in Hospital Pulau Pinang, MalaysiaClinical Audit / Quality Assurance / Quality Control

# • HOSPITAL PULAU PINANG

-Survey of Central Venous Catheter Care Bundle On Compliance and CLABSI Rate In Medical Wards, Hospital Pulau Pinang. Interventional

# • HOSPITAL PULAU PINANG

-Carbapenem Resistant Enterobacteriaceae Acquisition Rate and Risk Factors in General Intensive Care Unit ,Hospital Pulau PinangObservational

# • HOSPITAL PULAU PINANG

-An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of careInterventional

# • MINISTRY OF HEALTH

-An open-label, randomized, adaptive cross-over interventional study to evaluate the efficacy of tocilizumab versus corticosteroids in hospitalised COVID-19 patients with high risk of progressionInterventional

- National Institutes of Health (NIH)
- UNIVERSITY MALAYA MEDICAL CENTRE (UMMC)

-Olfactory and Gustatory Disturbances as a Clinical Presentation of Coronavirus Disease 2019 (COVID-19) Infection in Malaysia - A National Multicentre StudyObservational

# • HOSPITAL SULTANAH BAHIYAH, ALOR SETAR

-REAL-WORLD PRACTICE ON THE EFFICACY AND SAFETY OF ANTIVIRAL THERAPY IN THE MANAGEMENT OF COVID-19Observational

# • UNIVERSITI SAINS MALAYSIA HOSPITAL

-Malaysian Antiretroviral Therapy CohortRegistry / Biobanking / Clinical Database

# • HOSPITAL SUNGAI BULOH

-Randomized, Double -Blinded, Placebo Controlled Phase III Clinical Trial for the Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Healthy Population Aged 18 Years and Above in MalaysiaInterventional

• Institute of Medical Biology Chinese Academy of Medical Sciences

-Role of Early Steroid in Moderate COVID-19 Pneumonia: A Case Control StudyRegistry / Biobanking / Clinical Database

# • HOSPITAL PULAU PINANG

-Ivermectin Treatment Efficacy in Covid-19 High Risk Patients (I-TECH Study): A Multicenter Open-label Randomized Controlled Clinical TrialInterventional

# • MINISTRY OF HEALTH

-A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19Interventional

## IQVIA RDS Malaysia Sdn Bhd

-A Comparison of Pulse Methylprednisolone to Low-Dose Methylprednisolone in Critically ill patients with SARS-CoV-2 Pneumonia admitted to Intensive Care Unit, Penang General Hospital, Malaysia: a single-centered, retrospective, observational study. Observational

# HOSPITAL PULAU PINANG

(farah nadiah binti bidin)

-Efficacy of Ritonavir-boosted Nirmatrelvir on Disease Progression Among High-risk Hospitalized COVID-19 PatientsObservational

# HOSPITAL PULAU PINANG (Lee Soo Poh (042225333))

-A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Assess the Efficacy, Safety and Tolerability of Oral ARV-1801 Given in Combination with Intravenous Ceftazidime or Meropenem for Intensive Phase Therapy of Melioidosis in Hospitalized PatientsInterventional

• Arrevus, Inc.

-Update